Milosevic et al. showed that androgen deprivation increases prostate cancer oxygen levels, and this might explain the improved patient outcome that has been observed in many clinical trials using LHRH agonist in combination with RT [79]. The gene discussed is GNRH1; the disease is prostate carcinoma.